Toll-Like Receptor 4 Signaling and Inflammatory Response

Toll-like receptor 4 (TLR4) is a pattern recognition receptor central to innate immunity. It recognises lipopolysaccharide (LPS), an outer-membrane component of Gram-negative bacteria, via a co-receptor complex with MD-2 and CD14. Engagement of LPS induces conformational changes that recruit adaptor proteins—primarily MyD88 and TRIF—leading to sequential activation of NF-κB, MAP kinases and interferon regulatory factors. The MyD88-dependent cascade drives rapid production of pro-inflammatory cytokines such as tumour necrosis factor and interleukin-6, while the TRIF arm induces type I interferon and contributes to sustained inflammatory signalling. This dual pathway architecture allows TLR4 to coordinate antimicrobial defence, shape adaptive immunity and resolve tissue injury. Dysregulated TLR4 activation underlies sepsis, chronic inflammatory disorders and is implicated in sterile inflammation in cardiovascular and pulmonary diseases. Fine-tuning of TLR4 signalling through endogenous ligands, accessory proteins and negative regulators has become a focal point for therapeutic intervention. Structural studies continue to reveal how lipid A variants and accessory molecules modulate receptor activation, offering routes to design selective agonists or antagonists. Beyond its classical role in host defence, TLR4 signalling interfaces with other innate pathways—including caspase-mediated inflammasome activation—highlighting its role as an integrator of extra- and intracellular danger signals. Consequently, TLR4 remains a pivotal target for vaccines, adjuvants and anti-inflammatory drugs with global clinical relevance.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Toll-Like Receptor 4 Signaling and Inflammatory Response publication trend

The graph below shows the total number of articles in toll-like receptor 4 signaling and inflammatory response across all publications each year (not limited to Nature Index journals).

Technical terms

Toll-Like Receptor 4 (TLR4): A membrane-bound receptor that recognises lipopolysaccharide and initiates innate immune signalling.

Myeloid Differentiation Factor-2 (MD-2): A co-receptor that associates with TLR4 and binds lipid A to facilitate receptor activation.

MyD88: An adaptor protein that mediates early-phase NF-κB and MAP kinase signalling downstream of TLR4.

TRIF: An adaptor molecule that links TLR4 to interferon regulatory factors and late-phase inflammatory responses.

Lipopolysaccharide (LPS): A glycolipid component of Gram-negative bacterial outer membranes recognised as a pathogen-associated molecular pattern.

Inflammasome: A multiprotein complex that activates inflammatory caspases, leading to maturation of interleukin-1β and pyroptotic cell death.

References

1. The implication of dendritic cells in lung diseases: Immunological role of toll-like receptor 4. Genes & Diseases (2023).
2. TLR4 Signaling Pathway Modulators as Potential Therapeutics in Inflammation and Sepsis. Vaccines (2017).
3. Recognition of lipopolysaccharide pattern by TLR4 complexes. Experimental & Molecular Medicine (2013).
4. Recognition of lipid A variants by the TLR4-MD-2 receptor complex. Frontiers in Cellular and Infection Microbiology (2013).
5. Recent Advances in Lipopolysaccharide Recognition Systems. International Journal of Molecular Sciences (2020).
6. Lipopolysaccharide Recognition in the Crossroads of TLR4 and Caspase-4/11 Mediated Inflammatory Pathways. Frontiers in Immunology (2020).
7. The emerging role of Toll-like receptor 4 in myocardial inflammation. Cell Death & Disease (2016).